Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324158 | 0.79 | PDE4B (0.48) | L3MBTL1KDM4ECALM1PDE4BPDE4A | |
| SCHEMBL303557 | 0.78 | PDE4B (0.48) | L3MBTL1MAPK1KDM4ECALM1PDE4B | |
| SCHEMBL636038 | 0.78 | PDE4B (0.48) | L3MBTL1MAPK1KDM4ECALM1PDE4B | |
| SCHEMBL17262992 | 0.78 | KDM4E (0.46) | L3MBTL1MAPK1KDM4EKMT2ACALM1 | |
| SCHEMBL17262991 | 0.77 | SMN1; SMN2 (0.54) | L3MBTL1KDM4EKMT2ACALM1CA12 | |
| SCHEMBL16973517 | 0.77 | CALM1 (0.54) | KDM4ECALM1 | |
| SCHEMBL28323447 | 0.75 | LDHA (0.60) | L3MBTL1MAPK1KDM4EKMT2ALDHA | |
| SCHEMBL4638474 | 0.75 | MAPK1 (0.56) | L3MBTL1MAPK1KDM4EKMT2APDE4B | |
| SCHEMBL28274764 | 0.74 | LDHA (0.48) | KDM4EKMT2ACA12CA1CA2 | |
| SCHEMBL7211055 | 0.74 | ALDH1A1 (0.46) | L3MBTL1MAPK1KDM4EKMT2ACALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | AMGEN INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | AMGEN INC. | 2021-01-28 | — | — | US | disclosed |
| EP-3142748-B1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CELGENE CORP (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-2701701-B1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | CELGENE CORP (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | NEW YORK UNIVERSITY | 2017-03-30 | — | — | US | disclosed |
| EP-3142748-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | Celgene Corporation (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9480676-B2 | Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis | CELGENE CORPORATION (US) | 2016-11-01 | — | — | US | disclosed |
| EP-2420490-B1 | Method for the preparation of (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| US-9272035-B2 | Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases | CELGENE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150328187-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | AMGEN INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015175773-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | CELGENE CORPORATION (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2701701-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Celgene Corporation (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149251-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | CELGENE CORPORATION (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120276087-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | AMGEN INC. | 2012-11-01 | — | — | US | disclosed |
| EP-1485087-B1 | (+)-2- [1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE FOR USE IN TREATING PSORIASIS BY ORAL ADMINISTRATION | CELGENE CORP (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7276529-B2 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| US-7208516-B2 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060183788-A1 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION | 2006-08-17 | — | — | US | disclosed |
| US-20060183787-A1 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CELGENE CORPORATION | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183788-A1 | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | CHRM3, CHRM1, CHRM2 | L3MBTL1 4189/4885MAPK1 1929/4885KDM4E 1936/4885 |
| US-11260046-B2 | (+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | PDE4A, PDE4B, PDE2A | L3MBTL1 4232/4885MAPK1 1650/4885KDM4E 891/4885 |
| US-20150328187-A1 | USE OF PDE4 INHIBITORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS | PDE4A, CFTR, PDE4B | L3MBTL1 3980/4885MAPK1 3716/4885KDM4E 785/4885 |
| US-20170087129-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES WITH PDE4 MODULATORS | PDE4A, PDE4B, PDE3B | L3MBTL1 4694/4885MAPK1 2779/4885KDM4E 1051/4885 |
| US-20060183787-A1 | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione | AADAC, TPMT, MTX2 | L3MBTL1 4625/4885MAPK1 2114/4885KDM4E 1492/4885 |
| US-20120276087-A1 | METHODS AND COMPOSITIONS USING PDE4 INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | PDE4A, PDE4B, PDE4C | L3MBTL1 4754/4885MAPK1 2470/4885KDM4E 323/4885 |
| US-20210023051-A1 | (+)-2-[1-(3-ETHOXY-4- METHOXYPHENYL)-2-METHYLSULFONYLETHYL]- 4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | PDE4A, PDE4B, PDE2A | L3MBTL1 4232/4885MAPK1 1650/4885KDM4E 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.